Literature DB >> 29626663

A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.

Ella S Y Park1, Guilherme Rabinowits2, Ole-Petter R Hamnvik3, Linda R Dagi4.   

Abstract

We present the first reported case of Graves' orbitopathy induced by pembrolizumab, a new FDA-approved drug used for the treatment of multiple refractory solid tumors and classic Hodgkin lymphoma. Pembrolizumab elicits T-lymphocyte proliferation; we suspect that thyroid eye disease may result in some cases.
Copyright © 2018 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29626663     DOI： 10.1016/j.jaapos.2018.01.006

Source DB:  PubMed          Journal:  J AAPOS        ISSN： 1091-8531            Impact factor:   1.220


  5 in total

Review 1.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

Review 2.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

3.  Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.

Authors:  Alessandro Brancatella; Nicola Viola; Sandra Brogioni; Lucia Montanelli; Chiara Sardella; Paolo Vitti; Claudio Marcocci; Isabella Lupi; Francesco Latrofa
Journal:  Eur Thyroid J       Date:  2019-07-09

4.  Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study.

Authors:  Norio Okada; Shintaro Iwama; Takayuki Okuji; Tomoko Kobayashi; Yoshinori Yasuda; Eri Wada; Takeshi Onoue; Motomitsu Goto; Mariko Sugiyama; Taku Tsunekawa; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Hidetaka Suga; Ryoichi Banno; Tetsunari Hase; Masahiro Morise; Mitsuro Kanda; Kenji Yokota; Naozumi Hashimoto; Masahiko Ando; Yasushi Fujimoto; Masato Nagino; Yasuhiro Kodera; Mitsuhiro Fujishiro; Hideharu Hibi; Michihiko Sone; Hitoshi Kiyoi; Momokazu Gotoh; Yuichi Ando; Masashi Akiyama; Yoshinori Hasegawa; Hiroshi Arima
Journal:  Br J Cancer       Date:  2020-02-03       Impact factor: 7.640

Review 5.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.